X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PANACEA BIOTECH - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PANACEA BIOTECH SANOFI INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 33.6 171.2 19.6% View Chart
P/BV x 6.4 3.8 168.0% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
PANACEA BIOTECH
Mar-14
SANOFI INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs4,560149 3,066.6%   
Low Rs4,40082 5,346.3%   
Sales per share (Unadj.) Rs1,028.584.1 1,222.3%  
Earnings per share (Unadj.) Rs129.0-18.3 -704.4%  
Cash flow per share (Unadj.) Rs186.0-6.7 -2,776.3%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.683.7 900.3%  
Shares outstanding (eoy) m23.0361.25 37.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.4 317.3%   
Avg P/E ratio x34.7-6.3 -550.6%  
P/CF ratio (eoy) x24.1-17.2 -139.7%  
Price / Book Value ratio x5.91.4 430.8%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1747,074 1,458.4%   
No. of employees `0003.62.8 131.7%   
Total wages/salary Rs m3,5921,449 247.9%   
Avg. sales/employee Rs Th6,537.71,874.1 348.8%   
Avg. wages/employee Rs Th991.4527.0 188.1%   
Avg. net profit/employee Rs Th819.8-407.7 -201.0%   
INCOME DATA
Net Sales Rs m23,6865,154 459.6%  
Other income Rs m708100 709.4%   
Total revenues Rs m24,3945,254 464.3%   
Gross profit Rs m5,281-766 -689.2%  
Depreciation Rs m1,313711 184.7%   
Interest Rs m151,503 1.0%   
Profit before tax Rs m4,661-2,881 -161.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,69117 10,065.5%   
Profit after tax Rs m2,970-1,121 -264.9%  
Gross profit margin %22.3-14.9 -149.9%  
Effective tax rate %36.3-0.6 -6,220.5%   
Net profit margin %12.5-21.8 -57.6%  
BALANCE SHEET DATA
Current assets Rs m15,6733,810 411.3%   
Current liabilities Rs m6,6788,365 79.8%   
Net working cap to sales %38.0-88.4 -43.0%  
Current ratio x2.30.5 515.3%  
Inventory Days Days76156 48.8%  
Debtors Days Days2267 33.2%  
Net fixed assets Rs m8,09814,480 55.9%   
Share capital Rs m23061 375.7%   
"Free" reserves Rs m17,088903 1,892.2%   
Net worth Rs m17,3565,127 338.5%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m25,40019,433 130.7%  
Interest coverage x311.7-0.9 -34,013.4%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.90.3 351.6%   
Return on assets %11.82.0 598.3%  
Return on equity %17.1-21.9 -78.2%  
Return on capital %26.93.6 740.9%  
Exports to sales %24.524.5 99.9%   
Imports to sales %28.010.2 274.8%   
Exports (fob) Rs m5,8011,264 459.0%   
Imports (cif) Rs m6,627525 1,262.8%   
Fx inflow Rs m7,1451,539 464.2%   
Fx outflow Rs m6,846942 726.8%   
Net fx Rs m299597 50.1%   
CASH FLOW
From Operations Rs m3,226599 538.4%  
From Investments Rs m-1,555-438 355.1%  
From Financial Activity Rs m-1,818-303 600.8%  
Net Cashflow Rs m-147-141 104.0%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.6 2,400.0%  
FIIs % 14.6 1.3 1,123.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.6 44.5%  
Shareholders   15,184 10,259 148.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  CIPLA  ASTRAZENECA PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. DATSONS LABS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS